Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Neurodegenerative diseases are characterized by progressive cell loss leading to disruption of the structure and function of the central nervous system. Amyotrophic lateral sclerosis (ALS) was among the first of these disorders modeled in patient-specific iPSCs, and recent findings have translated into some of the earliest iPSC-inspired clinical trials. Focusing on ALS as an example, we evaluate the status of modeling neurodegenerative diseases using iPSCs, including methods for deriving and using disease-relevant neuronal and glial lineages. We further highlight the remaining challenges in exploiting the full potential of iPSC technology for understanding and potentially treating neurodegenerative diseases such as ALS.

Original publication

DOI

10.1016/j.stem.2021.12.008

Type

Journal article

Journal

Cell Stem Cell

Publication Date

06/01/2022

Volume

29

Pages

11 - 35

Keywords

ALS, FTD, astrocytes, clinical translation, disease modeling, microglia, motor neurons: cortical neurons, neurodegenerative diseases, pluripotent stem cells